Novo Nordisk : Diabetes franchise leading the way
>Insulin business in the spotlight - Novo Nordisk’s Q1 2024 results, reported this morning, beat expectations for revenues and margins: +2% ahead of expectations for the top line (DKK 65.5bn, +24% cc) and 9% better for EBIT (DKK 31.9bn, +30% cc). The GLP-1 franchise, driven by Ozempic (+65% cc), is keeping up the pace, with an increase in market share in its diabetes franchise and positive volume momentum (6% growth in GLP-1 prescriptions). But this release was m...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.